NCT04663399 IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)
| NCT ID | NCT04663399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2023-02-23 |
| Primary Completion | 2028-05-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2023-02-23 with a primary completion date of 2028-05-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 and 12 months of AIC treatment.
Eligibility Criteria
Inclusion Criteria: * Patient with an acute ischemic stroke for which treatment with mechanical thrombectomy is indicated, whether or not thrombectomy is performed, * Having received informed information about the study and having signed a consent to participate in the study (if this is not possible: information and consent of the trusted support person or family member if present; emergency inclusion if absent); * Affiliated or beneficiary of a social security scheme or equivalent. Non inclusion Criteria: * Pregnant or breast-feeding women * Patient benefiting from a legal protection measure Exclusion Criteria: None.
Contact & Investigator
Benjamin Maier, MD
PRINCIPAL INVESTIGATOR
Fondation Ophtalmologique Adolphe de Rothschild
Frequently Asked Questions
Who can join the NCT04663399 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04663399 currently recruiting?
Yes, NCT04663399 is actively recruiting participants. Contact the research team at bmaier@for.paris for enrollment information.
Where is the NCT04663399 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT04663399 clinical trial?
NCT04663399 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild. The principal investigator is Benjamin Maier, MD at Fondation Ophtalmologique Adolphe de Rothschild. The trial plans to enroll 1,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.